Medtronic’s MiniMed™ 670G hybrid closed-loop system, also known as ‘the world’s first artificial pancreas,’ has won FDA approval for use in children as young as seven years old.
The device was the first continuous glucose monitoring system with automated insulin delivery to be approved for use in adults in 2016.
The MiniMed™ 670G is the newest product from Medtronic and features the company’s most advanced technology which automates the delivery of a personalized amount of basal insulin every five minutes based on sensor glucose values.
“We are thrilled to be able to offer this advanced insulin management system to younger patients and their caregivers to help alleviate some of the burden associated with this unrelenting disease and to improve their quality of life,” said Dr. Francine Kaufman, chief medical officer and vice president of global regulatory, medical and clinical affairs of the Diabetes Group at Medtronic in a corporate
“This expanded age indication provides an important new treatment option for pediatric clinicians and parents of young children with type 1 diabetes, and further demonstrates our strong commitment to improving outcomes across the full diabetes care continuum